InFocus: Life Sciences & Healthcare e-newsletter - October 2007

In this issue we discuss:

• The importance of setting out the basis on which approval under a licence can be withheld
•  A recent CFI case reaffirms that communications between in-house counsel and internal clients are not privileged 
• Consolidation often means redundancies - How to deal with them
• Recent ratification of the London Agreement by France – What now?
• The Penalties Regulation – Does it mean double trouble?
• Apotex’s recent award of a compulsory licence in Canada to export to Rwanda
• Recent legislative developments in US law
• Update on environmental issues
• Clarification from the ECJ that TRIPS is part of the legislative framework of the EU
• Interim injunctions pending appeals

About Taylor Wessing's Life Sciences & Healthcare Group

Taylor Wessing's market-leading Life Sciences & Healthcare Group provides a top quality, multi-disciplinary service.  The Group combines Taylor Wessing’s top-rated intellectual property and venture capital lawyers with specialists from our highly acclaimed international corporate, corporate finance, employment and real estate practices.  We advise life sciences and healthcare businesses, those who fund them and those who work for them.

For more information about Taylor Wessing's Life Sciences & Healthcare Group, please click here.

For any legal enquiries, please contact Daniel Pavin or your usual contact at Taylor Wessing.  For any marketing and business development enquiries, please contact Sharon Philbey.